MiniMed receives FDA clearance for Fit tubeless insulin pump, revises FY2027 margin guidance

MiniMed announced that the U.S. Food and Drug Administration cleared its new Fit tubeless insulin pump, which can be worn for up to seven days and holds 300 units of insulin. The company said the U.S. launch will begin in spring 2027. MiniMed also disclosed a $162 million charge expected in Q3 2027, cutting its FY2027 adjusted EBITDA margin forecast to 11.3% from 16%. The firm’s underlying outlook remains unchanged.

The $162 million charge will lower MiniMed’s FY2027 profitability, as reflected in the reduced margin guidance (the company expects 11.3% versus 16% previously). Analysts note the margin hit offsets some of the positive impact of the new product approval, and the stock rose about 3.8% on the news.

  • 1The FDA cleared MiniMed Fit on November 16, 2026.
  • 2Fit is a tubeless insulin pump with up to seven days of wear and a 300‑unit insulin capacity.
  • 3MiniMed plans a phased U.S. launch in spring 2027.
  • 4The company expects a $162 million charge in Q3 2027.
  • 5Adjusted EBITDA margin guidance for FY2027 was cut to 11.3% from 16%.
  • 6MiniMed’s stock rose 3.78% to $18.67 following the announcement.

Sources